137 related articles for article (PubMed ID: 36658669)
21. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.
Kulik LM; Atassi B; van Holsbeeck L; Souman T; Lewandowski RJ; Mulcahy MF; Hunter RD; Nemcek AA; Abecassis MM; Haines KG; Salem R
J Surg Oncol; 2006 Dec; 94(7):572-86. PubMed ID: 17048240
[TBL] [Abstract][Full Text] [Related]
22. Profound transient thrombocytopenia associated with 90Yttrium microsphere therapy for inoperable hepatoma.
Yang CW; Yen HH; Su WW; Chen YY; Soon MS
South Med J; 2010 Dec; 103(12):1264-8. PubMed ID: 21037524
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies.
Omed A; Lawrance JA; Murphy G; Laasch HU; Wilson G; Illidge T; Tipping J; Zivanovic M; Jeans S
Clin Radiol; 2010 Sep; 65(9):720-8. PubMed ID: 20696299
[TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 (Y-90) resin microsphere therapy for patients with unresectable hepatocellular carcinoma. Identification of successful treatment response predictors and patient selection.
Arslan N; Ince S; Okuyucu K; San H; Alagoz E; Karadurmus N; Karaman B; Ercin CN
Ann Ital Chir; 2021; 92():623-631. PubMed ID: 35166222
[TBL] [Abstract][Full Text] [Related]
25. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
26. Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?
Inchingolo R; Cortese F; Pisani AR; Acquafredda F; Calbi R; Memeo R; Anagnostopoulos F; Spiliopoulos S
World J Gastroenterol; 2024 May; 30(18):2379-2386. PubMed ID: 38764771
[TBL] [Abstract][Full Text] [Related]
27. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
28. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of
Mahvash A; Chartier S; Turco M; Habib P; Griffith S; Brown S; Kappadath SC
BMC Gastroenterol; 2022 Mar; 22(1):151. PubMed ID: 35346070
[TBL] [Abstract][Full Text] [Related]
29. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
30. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
[TBL] [Abstract][Full Text] [Related]
31. Radionuclide therapy for hepatocellular carcinoma.
Lambert B; Van Vlierberghe H; Troisi R; Defreyne L
Acta Gastroenterol Belg; 2010; 73(4):484-8. PubMed ID: 21299159
[TBL] [Abstract][Full Text] [Related]
32. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience.
İnce S; Karaman B; Alagoz E; Karadurmuş N; Şan H; Erçin CN; Arslan N
J Gastrointest Cancer; 2017 Sep; 48(3):281. PubMed ID: 28634669
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.
Van Thai N; Thinh NT; Ky TD; Bang MH; Giang DT; Ha LN; Son MH; Tien DD; Lee HW
BMC Gastroenterol; 2021 May; 21(1):216. PubMed ID: 33980171
[TBL] [Abstract][Full Text] [Related]
34. Salvage surgery following downstaging of unresectable hepatocellular carcinoma.
Lau WY; Ho SK; Yu SC; Lai EC; Liew CT; Leung TW
Ann Surg; 2004 Aug; 240(2):299-305. PubMed ID: 15273555
[TBL] [Abstract][Full Text] [Related]
35. Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.
Wang TH; Huang PI; Hu YW; Lin KH; Liu CS; Lin YY; Liu CA; Tseng HS; Liu YM; Lee RC
PLoS One; 2018; 13(1):e0190098. PubMed ID: 29293557
[TBL] [Abstract][Full Text] [Related]
36. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
Lau WY; Kennedy AS; Kim YH; Lai HK; Lee RC; Leung TW; Liu CS; Salem R; Sangro B; Shuter B; Wang SC
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):401-7. PubMed ID: 20950954
[TBL] [Abstract][Full Text] [Related]
37. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
38. 90Y-TheraSpheres: The New Look of Yttrium-90.
Arnold CA; Pezhouh MK; Lam-Himlin D; Pittman ME; VandenBussche C; Voltaggio L
Am J Surg Pathol; 2019 May; 43(5):688-694. PubMed ID: 30720534
[TBL] [Abstract][Full Text] [Related]
39. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
[TBL] [Abstract][Full Text] [Related]
40. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
Memon K; Lewandowski RJ; Riaz A; Salem R
Recent Results Cancer Res; 2013; 190():207-24. PubMed ID: 22941023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
